Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;60(7):971-977.
doi: 10.1038/s41409-025-02600-7. Epub 2025 Apr 18.

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

Sebastian Galeano  1 , Carmem Bonfim  2 , Amado Karduss  3 , Gregorio Jaimovich  4 , Andrés Gómez-De León  5 , Gustavo Bettarello  6 , Anderson Simione  7 , Cinthya Correa  8 , Helen Baldomero  9 , Daniel Neumann  10 , Ana Lisa Basquiera  11 , Mariano Berro  12 , Guillermina Remaggi  13 , Ariel Amaru  14 , Fernando Barroso  15 , Adriana Seber  16 , Francisco Barriga  17 , Julia Palma  18 , Bárbara Puga  19 , Matías Sánchez  20 , Juan Manuel Herrera  21 , Calixto Hernández  22 , David Gómez-Almaguer  5 , Félix Gaytán Morales  23 , Guillermo J Ruiz-Argüelles  24 , Ninotzka Mendoza  25 , María Liz Benítez  26 , Alfredo Wong  27 , Carolina Pagés  28 , Marcos Hernández  29 , Dietger Niederwieser  30 , Damiano Rondelli  20 , Cristóbal Frutos  31
Affiliations

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

Sebastian Galeano et al. Bone Marrow Transplant. 2025 Jul.

Abstract

A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Andrés Gómez-De León: Honoraria: Janssen, Sanofi, Abbvie, Astellas, Amgen, BMS, Novartis. Advisory board: Pfizer, Janssen.

Figures

Fig. 1
Fig. 1. Disease indications for Hematopoietic Cell Transplantation (HCT) in 2022 in pediatrics.
a Relative proportion of allogeneic HCT; (b) relative proportion of autologous HCT.
Fig. 2
Fig. 2. Disease indications for Hematopoietic Cell Transplantation (HCT) in 2022 in adults.
a Relative proportion of allogeneic HCT; (b) relative proportion of autologous HCT.
Fig. 3
Fig. 3. GDP PPP per capita and TR in Latin American countries in 2022 as reported to LABMT.
HCT hematopoietic cell transplantation, LABMT Latin American Bone and Marrow Transplantation Society, TR Transplant Rate (number of HCT per 10 million population), GDP gross domestic product, PPP purchasing power parity, International $ International dollar (An international dollar would buy in the cited country a comparable amount of goods and services a U.S. dollar would buy in the United States).
Fig. 4
Fig. 4. Trends in Hematopoietic Cell Transplantation in the period 2019-2022 in Latin America.
a Numbers of autologous, allogeneic and total HCT reported to LABMT in 2019–2022. b Donor sources for first allogeneic HCT in the period 2019–2022. HCT hematopoietic cell transplantation, LABMT Latin American Bone and Marrow Transplantation Society, Fam HLA-id MRD human leukocyte antigen identical matched-related donor (HLA identical sibling and syngeneic), Fam HLA non id (haploidentical and other mismatched family donors), URD unrelated donor, CB cord blood, PB peripheral blood, BM bone marrow.
See this image and copyright information in PMC

References

    1. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39. - PMC - PubMed
    1. Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020;26:1247–56. - PubMed
    1. Latin American Bone Marrow Transplantation Society - LABMT. https://www.wbmt.org/member-societies-of-wbmt/labmt/ Accessed 05 May 2024.
    1. Worldwide Network for Blood & Marrow Transplantation - WBMT. https://www.wbmt.org Accessed 05 May 2024.
    1. Jaimovich G, Martinez Rolon J, Baldomero H, Rivas M, Hanesman I, Bouzas L, et al. Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplant. 2017;52:671–7. - PubMed

LinkOut - more resources